Our Mission
Every family deserves more time together. We built NephroSense AI to catch kidney disease early, so people can live longer, fuller lives with the ones they love.
Worldwide, more than 850 million people are affected by kidney disease, and CKD is projected to become the 5th leading cause of death by 2040. Chronic kidney disease affects 37M+ americans with ckd, yet 90% don't know they have it. By the time symptoms appear, 70% of kidney function is already lost. The tragedy is that a routine adult lab workup, vitals, and medical history can carry the signal to catch it early. The problem isn't data. It's translation. NephroSense AI was built to solve that problem: to give community health workers, primary care physicians, and health systems the tools to identify CKD risk early from a routine adult lab workup.
Health Equity at the Core
CKD disproportionately impacts underserved communities, especially those with the least access to nephrology specialists. NephroSense AI is designed for Federally Qualified Health Centers (FQHCs) and community clinics, where primary care providers can prioritize adult patients for follow-up using a routine adult lab workup and vitals. No new tests. No new hardware. A workflow that supports timely kidney follow-up where it matters most.
Leadership
Team
Co-Founder, President & Secretary
Recent IIM graduate. Dew leads NephroSense AI's go-to-market strategy and global operations, focused on bringing CKD screening to the communities where it is needed most.
Dr. Nisha Dubey
Co-Founder, Clinical Oversight
Physician trained at King George's Medical University. Dr. Dubey provides clinical oversight for NephroSense AI, ensuring the platform reflects real-world care and sound medical judgment.
Advisory Board
Advisors
Dr. Tushar Vachharajani, MD, MBA
Global Kidney Ambassador, Global Lead Advisor
Globally recognized interventional nephrologist with deep ties across the international nephrology community, including the International Society of Nephrology. Dr. Vachharajani guides NephroSense AI's global expansion, strategic relationships, and market development, drawing on his deep nephrology network and his role as a Global Kidney Ambassador.
Regulatory Advisor & Africa Strategy Lead
Pharmaceutical scientist and Senior Lecturer at the University of Greenwich (UCL PhD), with over a decade advising industry on pharmacovigilance, medical quality assurance, and regulatory strategy. Francis guides NephroSense AI's regulatory pathway and expansion across Africa.
Evidence-Based
Clinical Foundation
- 1
KDIGO 2024 Clinical Practice Guidelines for CKD Evaluation and Management
- 2
US adult clinical-cohort validation
- 3
21st Century Cures Act Clinical Decision Support guidance
- 4
FHIR R4 Standard for EHR Interoperability
- 5
ISN Global Kidney Health Atlas (2023), International Society of Nephrology
Medical Disclaimer
NephroSense AI is a Clinical Decision Support tool for use by licensed healthcare professionals with physician oversight. It does not provide medical diagnoses and does not replace any laboratory or diagnostic tests. By integrating a patient's existing clinical data faster, it helps clinicians prioritize who needs confirmatory testing and follow-up sooner. All clinical decisions must be made by qualified healthcare providers based on a complete patient evaluation.